Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg + Phenazopyridine Hydrochloride Tables, USP 200 mg
Phase 3Completed 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Uncomplicated Urinary Tract Infections
Conditions
Uncomplicated Urinary Tract Infections
Trial Timeline
Feb 1, 2012 → Feb 1, 2014
NCT ID
NCT01650051About Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg + Phenazopyridine Hydrochloride Tables, USP 200 mg
Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg + Phenazopyridine Hydrochloride Tables, USP 200 mg is a phase 3 stage product being developed by Amneal Pharmaceuticals for Uncomplicated Urinary Tract Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT01650051. Target conditions include Uncomplicated Urinary Tract Infections.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01650051 | Phase 3 | Completed |
Competing Products
13 competing products in Uncomplicated Urinary Tract Infections
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ZY19489 + Ferroquine (FQ) + Placebo | Zydus Lifesciences | Phase 1 | 33 |
| KLU156 + Coartem | Novartis | Phase 3 | 77 |
| Artemether-lumefantrine (COA566) | Novartis | Phase 2/3 | 65 |
| INE963 | Novartis | Phase 2 | 52 |
| KAE609 + SoC (Coartem) + KLU156 | Novartis | Phase 2 | 52 |
| KAF156 + Coartem + Lumefantrine Solid Dispersion Formulation | Novartis | Phase 2 | 52 |
| INE963 + KAE609 (Cipargamin) + SoC (Coartem) + KLU156 | Novartis | Phase 2 | 52 |
| KAF156 + LUM-SDF + Coartem | Novartis | Phase 2 | 52 |
| Co-artemether | Novartis | Approved | 85 |
| Broncho-munal® + Placebo | Sandoz Group | Phase 3 | 74 |
| Peramivir + Placebo | BioCryst Pharmaceuticals | Phase 2 | 47 |
| solithromycin + ceftriaxone + azithromycin | Allergy Therapeutics | Phase 3 | 72 |
| Sulopenem-Etzadroxil/Probenecid + Ciprofloxacin | Iterum Therapeutics | Phase 3 | 69 |
Other Products from Amneal Pharmaceuticals
CREXONT ERApproved
80
CREXONT ERApproved
80
Testosterone Topical Gel, 1.62% Metered Pump + AndroGel (testosterone gel) 1.62% Metered-Dose PumpPhase 3
72
Diclofenac Sodium Topical Gel, 1% + Voltaren Topical Gel, 1% + Vehicle Diclofenac Sodium Topical GelPhase 3
72
Phenazopyridine Hydrochloride + PlaceboPhase 3
72